BDSX

NEUTRALProduct

Biodesix, Inc.

2026-10-05

Price

$29.06

+4.83%

This is the 2026-10-05 snapshot — the signals and analysis for BDSX as of this single trading day.

View full BDSX research hub →

Score9.0Priority

Signals2/8 DNA3/13 Act · 1/4 Risk

SentimentNEUTRALScore: 8

Volume1.8xvs 20d avg

Analysis

Biodesix (BDSX) is undergoing High-Conviction Price Discovery as urgent institutional accumulation meets a major fundamental product catalyst. The recent advancement of tumor-informed and tumor-naive MRD testing programs in collaboration with Bio-Rad and Thermo Fisher has sparked aggressive buying, evidenced by 1.8x average volume and a PERFECT_STACK signal. This micro strength is amplified by a RISK_ON (RATES) macro regime, where soft payrolls and cooling wage growth are driving rate-cut expectations, creating an ideal tailwind for high-beta, long-duration diagnostic stocks to extend their relative outperformance.

Fired Signals

GOLDEN CROSSPERFECT STACKQUIET ACCUMULATIONSMA BOUNCEINSIDE OUTDISTRIBUTION

Key Takeaways

Actionable Thesis: Capitalize on the SMA_BOUNCE signal to ride the momentum from BDSX's recent MRD testing expansion and consensus price target upgrade to $37.54 [1.1.5].
Key Risk: With 52.5% annualized volatility and a massive 300%+ YTD run, the stock is highly vulnerable to profit-taking if the broader market's dovish Fed narrative falters.
What to Watch: Price action around the $26.04 line-in-the-sand; sustained volume above this level confirms the breakout is structural rather than a fleeting spike.

← Back to 2026-10-05 View Full BDSX History →Yahoo Finance &nearr;